Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C in a Tunisian population

##plugins.themes.academic_pro.article.sidebar##

Published Jul 20, 2016
Download
pdf
Vol. 94 No. 1 (2016): Issue Jan 2016

##plugins.themes.academic_pro.article.main##

Sondes Bizid
Riadh Bouali
Amani Ouedrani
Ali Mrabet
Hatem Ben Abdallah
Ezzeddine Ghazouani
Nabil Abdelli

Abstract

Background:  A polymorphism upstream of interleukin (IL)-28B was recently identified to be associated with a 2-fold difference in sustained virologic response (SVR) to pegylated interferon-alpha and ribavirin therapy in a large cohort of treatment-naive, adherent patients with chronic hepatitis C (CHC) virus genotype 1 (HCV-1) infection.
Aim: We sought to confirm the polymorphism's clinical relevance by intention-to-treat analysis evaluating on-treatment virologic response and SVR.
Methods: We perform a prospective study in gastroenterology unitof tunis’military hospital in collaboration with immunology unit, military center of blood transfusion and laboratory of biochemistry of childrens’ hospital of Tunis. HCV patients were genotyped as CC, CT or TT at the polymorphic site rs12979860 and TT, TG or GG at the polymorphic site rs8099917. Viral kinetics and rates of rapid virologic response (RVR, week 4) and SVR were compared by IL-28B type in a tunisian population.
Results: 154 patients including 80 healthy blood donors(sexratio: 1, mean age: 40.35 ±10.15 years) and 74 patients treated for CHC (39 men and 35 women; mean age = 51.7± 9.4 years) were enrolled. 35.6% of patients were genotyped as CC at the polymorphic site rs12979860 and 69.1% as TT at the polymorphic site rs8099917. The CC IL-28B type at rs12979860 was associated with a greater likelihood of SVR (77% vs 31.9%; p<0.001; OR: 7.11 [2.37-21.35]) compared with CT and TT. The CC IL-28B type at rs12979860 wasn’t associated with improved of rapid virologic response (RVR). In a multivariate logistic regression model, the rs12979860 CC genotype predicted SVR (p<0.001; OR: 7.11 IC95% [2.37-21.35]). The TT IL-28B type at rs 8099917 wasn’t associated with improved RVR and SVR compared with TG and GG.
Conclusion: In treatment-naive HCV patients treated with pegylated interferon and ribavirin, a polymorphism upstream CC at the site rs12979860 of IL-28B is associated with increased sustained virologic response and effectively predicts treatment outcome.

Keywords:

chronic hepatitis C, treatment, interleukine -28B

##plugins.themes.academic_pro.article.details##

References

  1. Debbeche R, Said Y, Ben Temime H, El Jery K, Bouzaïdi S, Salem M, Najjar T. Epidemiology hepatitis C in Tunisia. Tun Med 2013 ;91:86-91
  2. Triki H. Epidémiologie des virus des hépatites B, C et Delta dans la population générale et les cirrhoses hépatiques en Tunisie. Arch Inst Pasteur Tunis 1994;71 :403-6.
  3. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment induced viral clearance. Nature 2009 ; 461:391-401.
  4. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008;49:634-5.
  5. Asselah T. Genetic polymorphism and response to treatment in chronic hepatitis C: the future of personalized medicine. J Hepatol. 2010;52:452-4.
  6. Marcello T, Grakoul A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006 ;131:1887-98.
  7. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4.
  8. Tanaka Y, Nishida N, Sugiyama M, et al. Genomewide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
  9. Fischer J, Böhm S, Scholz M, Müller T, Witt H, George J et al. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology. 2012;55:1700-10.
  10. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010;139:821-827.
  11. Mangia A,Mottola L, Santoro R. Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients. World J Gastroenterol. 21, 2013; 19(47): 8924-8928.
  12. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45.
  13. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120-9.
  14. Falleti E, Bitetto D, Fabris C, Cussigh A, Fornasiere E, Cmet S et al. Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype.JClinImmunol. 2011;31:891-9
  15. Tillmann HL, Thompson A, Patel K, Wiese M, Tenckhoff H, Nischalke H, et al. IL28B polymorphism is associated with jaundice during acute HCV infection and is a strong predictor for spontaneous clearance in the prospective German anti-D cohort. JHepatol2010;52:S56.
  16. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronichepatitis C virus infection. N Engl J Med 2011;364:2405-16.
  17. Poordad F, Mc Cone J, Bacon BR, Bruno S, Manns MP et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
  18. Poordad F, Bronowicki JP, Gordon SC et al. IL28B polymorphisms predicts virological response in patients with hepatitis C genotype 1 treated with boceprevir combination therapy. J Hepatol 2011;54:S6.